LT2981255T - Empagliflozino terapiniai panaudojimo būdai - Google Patents

Empagliflozino terapiniai panaudojimo būdai

Info

Publication number: LT2981255T
Authority: LT; Lithuania
Prior art keywords: empagliflozin; therapeutic uses; therapeutic
Prior art date: 2013-04-05

Application number

LTEPPCT/EP2014/056655T

Other languages

English (en)

Inventor

Uli Christian BROEDL

David CHERNEY

Andreas Daiber

Maximilian VON EYNATTEN

Odd-Erik JOHANSEN

Gabriel Woojai KIM

Eric Williams Mayoux

Thomas Muenzel

Bruce A. PERKINS

Afshin SALSALI

Nima Soleymanlou

Hans-Juergen Woerle

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-05

Filing date

2014-04-03

Publication date

2022-11-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51787227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2981255(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-03 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2022-11-25 Publication of LT2981255T publication Critical patent/LT2981255T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Obesity (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

LTEPPCT/EP2014/056655T 2013-04-05 2014-04-03 Empagliflozino terapiniai panaudojimo būdai LT2981255T (lt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201361808807P	2013-04-05	2013-04-05
CA2812016A CA2812016A1 (en)	2013-04-05	2013-04-10	Pharmaceutical composition, methods for treating and uses thereof
US201361823041P	2013-05-14	2013-05-14
US201361835811P	2013-06-17	2013-06-17
US201361835809P	2013-06-17	2013-06-17
US201461942301P	2014-02-20	2014-02-20
PCT/EP2014/056655 WO2014161918A1 (en)	2013-04-05	2014-04-03	Therapeutic uses of empagliflozin

Publications (1)

Publication Number	Publication Date
LT2981255T true LT2981255T (lt)	2022-11-25

Family

ID=51787227

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/EP2014/056655T LT2981255T (lt)	2013-04-05	2014-04-03	Empagliflozino terapiniai panaudojimo būdai

Country Status (20)

Country	Link
US (2)	US20240156848A1 (lt)
EP (2)	EP4119136A1 (lt)
JP (4)	JP6325084B2 (lt)
KR (3)	KR20230074293A (lt)
CN (3)	CN105263485A (lt)
AU (2)	AU2014247091B2 (lt)
CA (2)	CA2812016A1 (lt)
DK (1)	DK2981255T3 (lt)
EA (1)	EA035181B1 (lt)
ES (1)	ES2930655T3 (lt)
FI (1)	FI2981255T3 (lt)
HR (1)	HRP20221368T1 (lt)
HU (1)	HUE060721T2 (lt)
IL (2)	IL276289B (lt)
LT (1)	LT2981255T (lt)
MX (2)	MX378422B (lt)
PL (1)	PL2981255T3 (lt)
PT (1)	PT2981255T (lt)
RS (1)	RS63721B1 (lt)
WO (1)	WO2014161918A1 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh)	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt)	2013-04-05	2019-02-19	Boehringer Ingelheim Int	Utilizações terapêuticas de empagliflozina
EA033286B1 (ru)	2013-04-18	2019-09-30	Бёрингер Ингельхайм Интернациональ Гмбх	Способ лечения или отсрочки развития хронической болезни почек
CN106714796A (zh) *	2014-05-16	2017-05-24	阿斯利康(瑞典)有限公司	用于抑制sglt2抑制剂的胰高血糖素分泌的方法
JP6561136B2 (ja)	2015-04-30	2019-08-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
WO2017064193A1 (en) *	2015-10-15	2017-04-20	Boehringer Ingelheim International Gmbh	Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
BR112018016001A2 (en) *	2016-03-16	2018-12-18	Boehringer Ingelheim International Gmbh	pharmaceutical composition, treatment methods and uses thereof
JP7625363B2 (ja)	2016-11-10	2025-02-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物、治療方法及びその使用
TWI835735B (zh) *	2017-06-12	2024-03-21	比利時商健生藥品公司	減少或預防第ii型糖尿病患者中心血管事件之方法
MA51203A (fr) *	2017-11-30	2020-10-07	Idorsia Pharmaceuticals Ltd	Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
MY210508A (en)	2018-07-19	2025-09-28	Astrazeneca Ab	Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CN109846898A (zh) *	2019-02-01	2019-06-07	同济大学	恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
IL322315A (en) *	2019-05-14	2025-09-01	Provention Bio Inc	Methods and preparations for preventing type 1 diabetes
KR20220038339A (ko) *	2019-07-23	2022-03-28	노파르티스 아게	Sglt 억제제, 예를 들어 sglt 1/2 억제제를 포함하는 치료
PE20211267A1 (es)	2019-08-30	2021-07-19	Astrazeneca Ab	Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
CN115300627B (zh) *	2021-05-08	2024-01-26	中南大学湘雅医院	钠-葡萄糖共转运蛋白2抑制剂的应用、一种药物组合物及其应用
CN115969844B (zh) *	2021-12-28	2024-04-02	首都医科大学附属北京同仁医院	Nox2特异性抑制剂在制备视网膜变性药物中的应用
KR20240099023A (ko) *	2022-12-20	2024-06-28	주식회사 티에치팜	나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 심혈관 질환 예방 또는 치료용 약학적 조성물
EP4640224A1 (en) *	2022-12-20	2025-10-29	THPharm Corp.	Pharmaceutical composition containing sodium-glucose transporter-2 inhibitor and angiotensin ii receptor blocker for prevention or treatment of non-alcoholic fatty liver disease
CN116212023A (zh) *	2022-12-30	2023-06-06	中山大学孙逸仙纪念医院	Sglt2抑制剂在制备预防或/和治疗血管钙化药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TW200817424A (en) *	2006-08-04	2008-04-16	Daiichi Sankyo Co Ltd	Benzylphenyl glucopyranoside derivatives
PE20090938A1 (es) *	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
KR101921934B1 (ko)	2009-02-13	2018-11-26	베링거 인겔하임 인터내셔날 게엠베하	글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
CN104138370A (zh) *	2009-02-13	2014-11-12	贝林格尔.英格海姆国际有限公司	用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
LT2395983T (lt) *	2009-02-13	2020-07-10	Boehringer Ingelheim International Gmbh	Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
UY32919A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) *	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es) *	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130035281A1 (en) *	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) *	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) *	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
BR112018016001A2 (en)	2016-03-16	2018-12-18	Boehringer Ingelheim International Gmbh	pharmaceutical composition, treatment methods and uses thereof

2013
- 2013-04-10 CA CA2812016A patent/CA2812016A1/en not_active Abandoned
2014
- 2014-04-03 KR KR1020237016366A patent/KR20230074293A/ko active Pending
- 2014-04-03 EP EP22188586.6A patent/EP4119136A1/en active Pending
- 2014-04-03 MX MX2015013948A patent/MX378422B/es unknown
- 2014-04-03 RS RS20221029A patent/RS63721B1/sr unknown
- 2014-04-03 LT LTEPPCT/EP2014/056655T patent/LT2981255T/lt unknown
- 2014-04-03 EA EA201500996A patent/EA035181B1/ru not_active IP Right Cessation
- 2014-04-03 CA CA2908621A patent/CA2908621C/en active Active
- 2014-04-03 HU HUE14715274A patent/HUE060721T2/hu unknown
- 2014-04-03 CN CN201480031475.5A patent/CN105263485A/zh active Pending
- 2014-04-03 PL PL14715274.8T patent/PL2981255T3/pl unknown
- 2014-04-03 FI FIEP14715274.8T patent/FI2981255T3/fi active
- 2014-04-03 KR KR1020217034100A patent/KR20210131442A/ko not_active Ceased
- 2014-04-03 HR HRP20221368TT patent/HRP20221368T1/hr unknown
- 2014-04-03 CN CN201811558246.5A patent/CN109512831A/zh active Pending
- 2014-04-03 MX MX2020013740A patent/MX2020013740A/es unknown
- 2014-04-03 ES ES14715274T patent/ES2930655T3/es active Active
- 2014-04-03 CN CN201811554457.1A patent/CN110075301A/zh active Pending
- 2014-04-03 JP JP2016505815A patent/JP6325084B2/ja active Active
- 2014-04-03 PT PT147152748T patent/PT2981255T/pt unknown
- 2014-04-03 DK DK14715274.8T patent/DK2981255T3/da active
- 2014-04-03 EP EP14715274.8A patent/EP2981255B1/en active Active
- 2014-04-03 AU AU2014247091A patent/AU2014247091B2/en active Active
- 2014-04-03 KR KR1020157031843A patent/KR102318207B1/ko active Active
- 2014-04-03 WO PCT/EP2014/056655 patent/WO2014161918A1/en not_active Ceased
2019
- 2019-04-12 AU AU2019202568A patent/AU2019202568B2/en active Active
2020
- 2020-03-04 JP JP2020036762A patent/JP7541641B2/ja active Active
- 2020-07-26 IL IL276289A patent/IL276289B/en unknown
2021
- 2021-10-24 IL IL287516A patent/IL287516B1/en unknown
2022
- 2022-02-18 JP JP2022023891A patent/JP2022069476A/ja active Pending
2024
- 2024-01-25 US US18/422,333 patent/US20240156848A1/en not_active Abandoned
- 2024-02-16 JP JP2024021883A patent/JP2024059725A/ja active Pending
2025
- 2025-07-21 US US19/274,809 patent/US20250345352A1/en active Pending

Also Published As

Publication number	Publication date
CA2908621A1 (en)	2014-10-09
JP2016515599A (ja)	2016-05-30
KR20150138859A (ko)	2015-12-10
AU2019202568A1 (en)	2019-05-02
US20240156848A1 (en)	2024-05-16
FI2981255T3 (fi)	2022-12-15
JP2022069476A (ja)	2022-05-11
KR102318207B1 (ko)	2021-10-28
EA035181B1 (ru)	2020-05-12
MX378422B (es)	2025-03-10
PT2981255T (pt)	2022-11-21
DK2981255T3 (da)	2022-11-14
AU2019202568B2 (en)	2021-04-01
ES2930655T3 (es)	2022-12-20
JP2020109100A (ja)	2020-07-16
IL287516B1 (en)	2023-07-01
IL276289A (en)	2020-09-30
IL276289B (en)	2022-02-01
JP7541641B2 (ja)	2024-08-29
PL2981255T3 (pl)	2023-01-09
US20250345352A1 (en)	2025-11-13
WO2014161918A1 (en)	2014-10-09
HUE060721T2 (hu)	2023-04-28
AU2014247091B2 (en)	2019-01-17
CA2908621C (en)	2022-08-16
CN105263485A (zh)	2016-01-20
MX2020013740A (es)	2022-10-27
EP4119136A1 (en)	2023-01-18
MX2015013948A (es)	2016-07-20
JP6325084B2 (ja)	2018-05-16
EP2981255A1 (en)	2016-02-10
AU2014247091A1 (en)	2015-09-17
IL287516A (en)	2021-12-01
CN109512831A (zh)	2019-03-26
CN110075301A (zh)	2019-08-02
RS63721B1 (sr)	2022-12-30
JP2024059725A (ja)	2024-05-01
HRP20221368T1 (hr)	2023-01-06
EA201500996A1 (ru)	2016-04-29
CA2812016A1 (en)	2014-10-05
EP2981255B1 (en)	2022-09-14
KR20210131442A (ko)	2021-11-02
KR20230074293A (ko)	2023-05-26

Publication	Publication Date	Title
IL287516A (en)	2021-12-01	Medicinal uses of empagliflozin
HRP20190101T1 (hr)	2019-03-08	Terapeutske uporabe empagliflozina
IL241101A0 (en)	2015-11-30	Medicinal uses of empagliflozin
HRP20180684T1 (hr)	2018-06-01	Kombinacija lijekova
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
EP2922514A4 (en)	2016-01-13	BI-RADIAL PATIENT INTERFACE
PT2953948T (pt)	2017-12-12	Antagonistas de integrina fluorada
LT3007726T (lt)	2020-09-10	Tautopatijos gydymo būdai
PL2981271T3 (pl)	2019-05-31	Zastosowania terapeutyczne empagliflozyny
PT3626270T (pt)	2024-01-11	Tratamento de doenças cardiovasculares
DK2767269T3 (da)	2019-05-06	Terapeutisk anordning
PL2991633T3 (pl)	2019-10-31	Terapia bakteriofagami
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
EP2988738A4 (en)	2016-11-09	THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
IL239971A0 (en)	2015-08-31	Isometheptene isomer
DK2976101T3 (da)	2020-11-23	Behandlingsfremgangsmåde
FI20136034A7 (fi)	2014-12-15	Sauna
DK3041506T3 (da)	2023-02-27	Behandlingsfremgangsmåde
ES1098808Y (es)	2014-04-25	Juguete-instrumento de muneco bailarin
UA28711S (uk)	2015-01-12	Масажер
EP2958932A4 (en)	2016-08-10	THERAPEUTICS
EP2996684A4 (en)	2016-11-30	THERAPEUTIC PROCEDURES
UA26527S (uk)	2014-03-11	Комплект посуду
UA28339S (uk)	2014-11-10	Медичний пристрій-шприц
UA28338S (uk)	2014-11-10	Медичний пристрій-шприц